Clinical Trials Logo

Mantle Cell Lymphoma clinical trials

View clinical trials related to Mantle Cell Lymphoma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06341556 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line immunochemotherapy

NCT ID: NCT06340737 Recruiting - Clinical trials for Mantle Cell Lymphoma

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Start date: March 29, 2024
Phase: Phase 1
Study type: Interventional

This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and duration of response (DOR). An evaluable participant is one who completes leukapheresis, lymphodepleting chemotherapy and CART infusion.

NCT ID: NCT06339255 Recruiting - Clinical trials for Mantle Cell Lymphoma

Italian Observational Study on CAR-T Therapy for Lymphoma

CART-SIE
Start date: October 30, 2019
Phase:
Study type: Observational

The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting. Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.

NCT ID: NCT06192888 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Start date: January 8, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma

NCT ID: NCT06151730 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Start date: January 5, 2024
Phase:
Study type: Observational

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

NCT ID: NCT06106841 Recruiting - Clinical trials for Mantle Cell Lymphoma

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Start date: October 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.

NCT ID: NCT06054776 Recruiting - Clinical trials for Mantle Cell Lymphoma

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Start date: June 10, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Glofitamab is a class of medications called bispecific antibodies. Bispecific antibodies are designed to simultaneously bind to T cells and cancer cell antigens, leading to T-cell activation, proliferation, and cancer cell death. Giving acalabrutinib, obinutuzumab, and glofitamab together may be a safe and effective treatment for patients with relapsed or refractory mantle cell lymphoma.

NCT ID: NCT06029309 Recruiting - Clinical trials for Mantle Cell Lymphoma

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

ZANU-TAFA
Start date: May 3, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma. Another purpose is to assess how well the combination treatment works in patients with the study disease.

NCT ID: NCT06026319 Recruiting - Clinical trials for Mantle Cell Lymphoma

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Start date: October 26, 2023
Phase: Phase 1
Study type: Interventional

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: - CD79b-19 CAR T cells - Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

NCT ID: NCT06022029 Recruiting - Bladder Cancer Clinical Trials

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

ON-5001
Start date: October 13, 2023
Phase: Phase 1
Study type: Interventional

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.